Wedbush Reaffirms Outperform Rating for Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “outperform” rating reaffirmed by analysts at Wedbush in a report issued on Wednesday, Marketbeat reports. They presently have a $8.00 price target on the stock.

Several other research firms have also recently weighed in on HOWL. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Werewolf Therapeutics in a report on Wednesday. JMP Securities decreased their target price on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a report on Tuesday, January 14th.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $1.21 on Wednesday. The business’s fifty day moving average price is $1.36 and its 200-day moving average price is $1.82. The stock has a market capitalization of $53.92 million, a price-to-earnings ratio of -0.79 and a beta of 0.37. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10. Werewolf Therapeutics has a 1-year low of $1.03 and a 1-year high of $6.89.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%. On average, equities analysts predict that Werewolf Therapeutics will post -1.56 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HOWL. PFM Health Sciences LP grew its position in shares of Werewolf Therapeutics by 4.9% during the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after purchasing an additional 157,673 shares in the last quarter. Deutsche Bank AG grew its position in shares of Werewolf Therapeutics by 450.7% during the fourth quarter. Deutsche Bank AG now owns 101,626 shares of the company’s stock valued at $150,000 after purchasing an additional 83,172 shares in the last quarter. State Street Corp grew its position in shares of Werewolf Therapeutics by 12.4% during the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after purchasing an additional 52,528 shares in the last quarter. Levin Capital Strategies L.P. purchased a new position in shares of Werewolf Therapeutics during the fourth quarter valued at about $74,000. Finally, JPMorgan Chase & Co. grew its position in Werewolf Therapeutics by 372.4% in the fourth quarter. JPMorgan Chase & Co. now owns 62,928 shares of the company’s stock worth $93,000 after acquiring an additional 49,608 shares in the last quarter. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.